Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209949 · ClinicalTrials.gov registry record · Phase 4
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01209949: Completed Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
NCT01209949 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 30 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209949, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.
Primary Outcome
Number of participants who were a Success (Subject's Global Assessment of 'Clear or 'Almost Clear') at week 12. Subject's Global Assessment is measured on a scale (Clear, Almost Clear, Mild, Moderate, Severe, Very Severe) with Clear being best and Very Severe being worst.
Conditions Studied
Interventions
- DRUG Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
Study Locations (1)
Texas
- Thomas J. Stephens and Associates - Carrollton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
What the finished NCT01209949 record still lists
NCT01209949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Adapalene 0.1% and Benzoyl Peroxide 2.5% gel is the first listed.
NCT01209949 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01209949 about?
NCT01209949 is a clinical study titled "Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris". The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.
What is the current status of trial NCT01209949?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2010-10. Estimated completion is 2011-01.
What conditions does trial NCT01209949 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01209949?
The interventions under investigation include: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel (DRUG).
Who is sponsoring clinical trial NCT01209949?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01209949 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01209949's enrollment target sits among peer trials
30 52nd of 67 higher than 13 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
-
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia